SlideShare a Scribd company logo
ANTIDEPRESSANTS
BY
UKPONG DISE-UTIBE P.
PSCHIATRY POSTING [M3]
UNIVERSITY OF UYO TEACHING HOSPITAL
JANUARY 2023
OUTLINE
• INTRODUCTION
• BRIEF HISTORY OF ANTIDEPRESSANT USE
• THERAPEUTICS OF ANTIDEPRESSANT USE
• GOOD AND BAD NEWS OF ANTIDEPRESSANT TREATMENT
• USE OF ANTIDEPRESSANTS ACROSS LIFE CYCLES
• BIOLOGICAL BASIS OF DEPRESSION
• CLASSIFICATION OF ANTIDEPRESSANTS
• MECHANISM OF ACTION, USES AND SIDE EFFECTS OF EACH
ANTIDEPRESSANT
• SUMMARY OF THE GENERAL USES OF ANTIDEPRESSANTS
INTRODUCTION
• These are varied groups of therapeutic agent that significantly elevate the
mood of depressed patients. Despite the duration of the discovery of
these agents, the precise pharmacological activity of some of them remain
unexplained.
• The first group of antidepressants to be used were the tricyclic
antidepressants which were closely followed by the monoamine oxidase
inhibitors.
• Recently, a series of highly successful innovative agents have been
introduced. These include, selective serotonin reuptake inhibitors (SSRI),
Selective Noradrenalin reuptake inhibitors (SNRIS), dual SSRI and SNRI,
dual 5HT2 antagonist/5HT reuptake inhibitors, NE/DA reuptake inhibitors.
BRIEF HISTORY OF ANTIDEPRESSANT USE
• The history of antidepressants began, by chance, in the 1950s.
Chemists developing a new treatment for tuberculosis tested the drug
iproniazid on patients at Seaview Hospital on Staten Island. It was a
crucial step in the history of depression treatment, as these patients
experienced a dramatic change in well-being. Formerly lethargic and
sad, they now reported better mood, increased appetite, and
improved sleep.
THERAPEUTICS OF ANTIDEPRESSANT USE
The Five R’s of Antidepressant Treatment
3 R’s use to describe improvement
Response
(At least 50% Reduction in symptom)
Remission
(All symptoms disappear for 6-12 months)
Recovery
(Symptoms disappear for over 12 months)
• 2 R’s used to describe worsening
• Relapse
• (Worsening before remission)
• Reoccurrence
• (Worsening after recovery)
Good news/Bad news about Antidepressant
treatment
• Good news
• All antidepressants show about the same response (getting
better) after 8 weeks (50 - 75% of patients)
• Bad news
• Raising the bar of “getting better” dims the success rate; 50%
may show remission in 6 months; 75% in 12 months.
• All antidepressants significantly reduce relapse rates during the
first 6-12 months after initial response to the medication.
Use of antidepressants across life cycle
• Children: currently no antidepressant has been expressly approved
for treatment of depression in children (used in OCD)
• Adolescents: Better than children as in adults. Synaptic restructuring
generally occurs after the age of 6 years.
Biological Basis of Depression
• 1. Monoamine Hypothesis:
1st major theory about biological etiology of depression. It
predicts that the underlying pathophysiologic basis of depression
is a depletion in the levels of serotonin, norepinephrine, and/or
dopamine in the central nervous system.
• 2. Neurotransmitter Receptor Hypothesis.
Problem with receptors for the key monoamine neurotransmitters
• 3. Monoamine Hypothesis of Gene Expression.
BASED ON:
• Lack of clear and convincing evidence of absolute monoamine
deficiency
• No clear and convincing evidence of that excess or deficiencies of
mono amines account for depression
• Clear evidence that systems do not respond normally.
• POSSIBILITIES:
• Pseudo monoamine deficiency due to a deficiency in signal transduction
from neurotransmitter to receptor (molecular functioning)
• Abnormal molecular activity; post receptor (2nd messenger) problems with
intracellular transcription factors that control gene regulation.
• Abnormality in signal transduction from monoamine receptors.
• Brain Derived Neurotrophic Factor (BDNF) may be responsible for repeated
depressive episodes and poor response to treatment (supported by
decrease in size of hippocampal neurons and impaired function in
depression).
• 4. Neurokinin Hypothesis of Emotional Dysfunction
• Presence of neurokinins in amygdala
• Presence of neurokinins in areas where mono amines are in
abundance.
•
CLASSIFICATION OF ANTIDEPRESSANTS
1. MONOAMINEOXIDASE INHIBITORS
A. REVERSIBLE INHIBITORS OF MAO-A (RIMAS)
• Moclobemide,
• Clorgyline
B. IRREVERSIBLE INHIBITIORS OF MAO-A
• Selegiline (Emsam),
• phenelzine (Nardil),
• tranylcypromine (Parnate),
• isocarboxazid (Marplan).
2. Tricyclic antidepressants (TCAs)
A. NA + 5-HT reuptake inhibitors
• Imipramine,
• Amitriptyline
• Trimipramine,
• Doxepin,
• Dothiepin,
• Clomipramine
B. Predominantly NA reuptake inhibitors
• Desipramine,
• Nortriptyline,
• Amoxapine,
• Reboxetine
3. Selective serotonin reuptake inhibitors (SSRIs)
• Fluoxetine,
• Fluvoxamine,
• Paroxetine,
• Sertraline,
• Citalopram,
• Escitalopram,
• Dapoxetine
4. Serotonin and noradrenaline reuptake inhibitors (SNRIs)
• Venlafaxine,
• Duloxetine
5. Atypical antidepressants
Trazodone,
• Mianserin,
• Mirtazapine,
• Bupropion,
• Tianeptine,
• Amineptine,
• Atomoxetine
IRREVERSIBLE INHIBITIORS OF MAO-A
MECHANISM OF ACTION
• Uniquely among antidepressants, MAOI’s increase synaptic levels of
all three catecholamines (serotonin, norepinephrine, and dopamine).
• Because of this, MAOI’s are among the most effective of all
antidepressants, especially in the subtype of depression known as
atypical depression .
• Atypical depression is characterized by mood reactivity, interpersonal
rejection sensitivity, increased appetite, hypersomnia, and leaden
paralysis (the sensation that one’s arms are too heavy to lift).
• Selegiline is unique, however, in that it is sele ctive for the B-subtype
of MAO, whereas the other three are non-selective and hit both
MAO-A and MAO-B.
SIDE EFFECTS
• anticholinergic and
• antihistaminic effects discussed with the tricyclics,
• multiple drug-drug interactions,
• withdrawal symptoms, and potentially
• fatal hypertensive events.
• Because of these considerations, MAOI’s are not prescribed very
often in modern psychiatry and are typically used as a “last resort”
after a patient has failed multiple other medications from several
different classes first.
INTERACTIONS
• (i) Cheese reaction Certain varieties of cheese, beer, wines, pickled
meat and fish, yeast extract contain large quantities of tyramine,
dopa, etc. In MAO inhibited patients these indirectly acting
sympathomimetic amines escape degradation in the intestinal wall
and liver → reaching into systemic circulation they displace and
release large amounts of NA from transmitter loaded adrenergic
nerve endings → hypertensive crisis, cerebrovascular accidents.
When such a reaction occurs, it can be treated by i.v. injection of a
rapidly acting α blocker, e.g. phentolamine. Prazosin or
chlorpromazine are alternatives.
• (ii) Cold and cough remedies They contain ephedrine or other
sympathomimetics—hypertensive reaction can occur.
• (iii) Reserpine, guanethidine, tricyclic antidepressants Excitement, rise in BP and
body temperature can occur when these drugs are given to a patient on MAO
inhibitors. This is due to their initial NA releasing or uptake blocking action.
• (iv) Levodopa Excitement and hypertension occur due to increase in biological
t½ of DA and NA that are produced from levodopa.
• (v) Antiparkinsonian anticholinergics Hallucinations and symptoms similar to
those of atropine poisoning occur.
• (vi) Barbiturates, alcohol, opioids, antihistamines Action of these drugs is
intensified and prolonged. Respiration may fail.
• (vii) Pethidine High fever, sweating, excitation, delirium, convulsions and severe
respiratory depression have occurred. The most accepted explanation is— MAO
inhibitors retard hydrolysis of pethidine but not its demethylation. Thus, excess
of norpethidine (normally a minor metabolite—see p. 475) is produced which
has excitatory actions.
REVERSIBLE INHIBITORS OF MAO-A
(MOCLOBEMIDE)
• MECHANISM OF ACTION
• It is a reversible and selective MAO-A inhibitor with short duration of
action; full MAO activity is restored within 1–2 days of stopping the drug.
Because of competitive enzyme inhibition, tyramine is able to displace it
from the enzyme, so that potentiation of pressor response to ingested
amines is minor, and dietary restrictions are not required. Clinical trials
have shown moclobemide to be an efficacious antidepressant, comparable
to TCAs, except in severe cases. and is safer in overdose.
• This makes it a particularly good option in elderly patients and in those
with heart disease.
• Dose: 150 mg BD–TDS (max 600 mg/day)
• RIMAREX, TRIMA 150, 300 mg tabs.
SIDE EFFECTS
• Nausea,
• dizziness,
• headache,
• insomnia,
• rarely excitement and
• liver damage.
INTERACTIONS
• Chances of interaction with other drugs and alcohol are remote, but
caution is advised while coprescribing pethidine, SSRIs and TCAs.
• NOTE: It has emerged as well tolerated alternative to mild and
moderate depression and for social phobia
TRICYCLIC ANTIDEPRESSANTS
• Now we come to the oldest class of antidepressants, and some of the
first drugs to be officially prescribed for that purpose: the tricyclic
antidepressants (often shortened to just “tricyclics” or “TCA’s”). You
can generally recognize TCA’s by their name, as they usually have the
suffixes–triptyline (as in amitriptyline and nortriptyline) or
–ipramine (as in clomipramine and imipramine).
MECHANISM OF ACTION OF TCA
• First, TCA’s inhibit the reuptake of both serotonin and norepinephrine
(similar to SNRI’s). This is the action that is primarily responsible for
their antidepressant effects.
• Second, TCA’s antagonize acetylcholine and histamine , which
accounts more for their side effect profile than their antidepressant
efficacy.
• Third, TCA’s are known to work as sodium and calcium channel
inhibitors as well. Clinically, this property may account for some of
their analgesic properties (like duloxetine, they are helpful for some
chronic pain conditions).
SIDE EFFECTS OF TCA
• Anticholinergic side effects, including dry mouth, itchy eyes, blurry
vision, constipation, urinary retention, memory impairment, and
increased body temperature.
• Antagonism of histamine results in a diphenhydramine-like effect,
with drowsiness and sedation being common complaints while on a
tricyclic.
• TOXICITY OF TCA OVERDOSE
• They have a therapeutic index of 7, (meaning that taking just 7 times
the normal amount of the drug could cause death). Slowing these ion
channels affects both cardiac and neuronal conduction, leading to
arrhythmias and altered mental status or coma.
NOTE:
A wide QRS in the context of suspected overdose is likely TCA
overdose . Treatment is sodium bicarbonate .
• In summary
• TCA’s act as agonists at two neurotransmitters, antagonists at another
two, and inhibitors of two ion channels.
PNEUMONIC
TCA’s increase serotonin and norepinephrine , block acetylcholine and
histamine , and inhibit sodium and calcium ion channels.
TCA’s affect T rans, C hans, and A ns.
INTERACTIONS
• 1. TCAs potentiate directly acting sympathomi-metic amines (present
in cold/asthma remedies). Adrenaline containing local anaesthetic
should be avoided. However, TCAs attenuate the action of indirect
sympathomi-metics (ephedrine, tyramine).
• 2. TCAs abolish the antihypertensive action of guanethidine and
clonidine by preventing their transport into adrenergic neurones.
• 3. TCAs potentiate CNS depressants, including alcohol and
antihistaminics.
• 4. Phenytoin, phenylbutazone, aspirin and
Chlopromazine(antipsychotic) can displace TCAs from protein binding
sites and cause transient overdose symptoms.
• 5. Phenobarbitone competitively inhibits as well as induces imipramine
metabolism.
• Carbamazepine and other enzyme inducers enhance metabolism of
TCAs.
• 6. SSRIs inhibit metabolism of several drugs (see later) including TCAs—
dangerous toxi-city can occur if the two are given concur-rently.
• 7. By their anticholinergic property, TCAs delay gastric emptying and
retard their own as well as other drug’s absorption. However, digoxin
and tetracyclines may be more completely absorbed. When used
together, the anticho-linergic action of neuroleptics and TCAs may add
up.
• 8. MAO inhibitors—dangerous hypertensive crisis with excitement and
hallucinations has occurred when given with TCAs.
IMIPRAMINE
The first antidepressant ever developed! Imipramine is a
prototypical TCA, so everything we’ve talked about thus far applies.
One thing that sets imipramine apart is that it is sometimes used for
management of nocturnal enuresis, or bed wetting, in children.
The anticholinergic effect of imipramine prevents the bladder from
contracting, thus holding the urine. Because of its side effects, it is not
used as a first-line agent but can be useful in refractory cases
CLOMIPRAMINE
• Clomipramine (Anafranil) is another TCA that can be used to treat
depression. However, clomipramine is unique in that it is considered
to be the gold-standard for medication treatment of obsessive-
compulsive disorder (OCD) , as it was found in several randomized
controlled trials to be more effective than SSRI’s. Due to its higher
side effect burden, however, clomipramine should be reserved for
more severe or refractory cases of OCD, with SSRI’s as the first-line
option.
AMITRIPTYLINE AND NORTRIPTYLINE
• Two other commonly prescribed TCA’s are amitriptyline (Elavil) and
nortriptyline (Pamelor). Both are prototypical TCA’s, but in addition to
depression, you will also see them prescribed for chronic pain issues,
such as diabetic peripheral neuropathy, chronic low back pain, or
pelvic pain.
• Compared to amitriptyline, nortriptyline tends to be much less
associated with sedation, orthostatic hypotension, and falls (owing to
less antihistaminergic and anticholinergic effects). For this reason, it is
preferred for elderly patients for whom sedation and falls can be very
big deals.
• Amoxapine
• This tetracyclic compound is unusual in that it blocks dopamine D2
receptors in addition to inhibiting NA reuptake. It is chemically related
to the antipsychotic drug loxapine and has mixed antidepressant +
neuroleptic properties—offers advantage for patients with psychotic
depression. Risk of extrapyramidal side effects is also there. Seizures
(including status epilepticus) occur in its overdose.
• Reboxetine
• This is a newer selective NA reuptake blocker with weak effect on 5-
HT reuptake. Antimuscarinic and sedative actions are minimal. It
appears to produce fewer side effects and may be safer in overdose
than the older TCAs.
• Side effects are insomnia, palpitation, dry mouth, constipation,
sexual distress and urinary symptoms.
Dose: NAREBOX 4, 8 mg tab.
4 mg BD or 8 mg OD
SELECTIVE SEROTONIN REUPTAKE INHIBITORS
(SSRIs)
• These drugs work by inhibiting the reuptake of serotonin, effectively
increasing the amount of serotonin active and available in the
synaptic cleft
• One thing to counsel patients on before starting an SSRI is how long
they can take to work. In multiple studies, it has been shown that full
treatment efficacy is often not reached until 4 to 6 weeks (although
typically some benefit is noticed within the first 2 weeks). Patients
can sometimes feel like stopping the drug early, as the side effects
(like diarrhea) are immediate, while the desired effects can take
several weeks.
Antidepressant Profile of SSRI
• Starting dose usually the same as the maintenance dose.
• Response is frequently complete with remission of symptoms.
• Target symptoms do not worsen when treatment initiated.
SIDE EFFECTS
• Commonly cause;
• nausea and GI upset,
• headache,
• restlessness, and insomnia;
• may be less effective for severe depressive episodes;
• Contraindications: manic episode, concomitant use of MAOIs
• Interactions: alcohol, anticoagulants, anticonvulsants, antipsychotics,
BDZs, B-blockers
Fluoxetine
• A bicyclic compound, is the first SSRI to be introduced, and the longest
acting.
• Its plasma t½ is 2 days and that of its active demethylated metabolite is 7–
10 days. It has been approved for use in children 7 years or older for
depression and OCD on the basis of similar efficacy and side effect profile
as in adults, but should be given to children only when psychotherapy fails.
• Agitation and dermatological reactions are more frequent than other SSRIs
Because of slower onset of antidepressant effect, it is considered less
suitable for patients needing rapid effect, but is more appropriate for
poorly compliant patients. Its stimulant effect could worsen patients
showing agitation.
• Fluoxetine has a very long half-life, lasting 1 to 2 weeks
Sertraline
• This SSRI has gained popularity, because in clinical trials fewer
patients stopped sertraline due to side effects.
• Efficacy in juvenile depression has been demonstrated, and it is
recommended for anxiety and post-traumatic stress disorder (PTSD)
as well.
• Drug interactions due to inhibition of CYP isoenzymes are less likely
to occur with this SSRI. Its plasma t½ is 26 hours and it produces a still
longer-lasting active metabolite.
• NOTE: Sertraline has more GI side effects but is safe when pregnant
or breastfeeding .
Citalopram
• This SSRI shares with sertraline a lower propensity to cause drug
interactions.Its t½ is 33 hours and no active metabolite is known.
However, few deaths due to overdose of citalopram are on record,
because of which it is to be avoided in patients likely to attempt
suicide. Citalopram is the preferred SSRI for mood disorders in
premenstrual syndrome.
Escitalopram
• It is the active S(+) enantiomer of citalopram, effective at half the
dose, with similar properties. Side effects are milder and safety is
improved.
Dapoxetine
• A SSRI which has been developed and is being promoted for delaying
premature ejaculation, a property common to many SSRIs and some
TCAs.
• Dapoxetine acts rapidly and can be taken 1 hour before sexual
intercourse.
• Combined with behavioural therapies, it has been found to help many
sufferers.
• Side effects are nausea, vomiting, loose motions, headache, dizziness
and occasionally insomnia.
• Dose: 60 mg taken 1 hour before intercourse; older patients 30 mg.
• Mode of action: 5-HT and NE reuptake inhibition.
• • Common adverse effects: nausea, GI upset, constipation, loss of
appetite, dry mouth, dizziness, agitation, insomnia, sexual
dysfunction, headache, nervousness, sweating, weakness
SEROTONIN AND NORADRENALINE REUPTAKE
INHIBITORS (SNRIs)
• 1. Venlafaxine
• A novel antidepressant referred to as SNRI, because it inhibits uptake of both NA
and 5-HT but, in contrast to older TCAs, it does not interact with cholinergic,
adrenergic or histaminergic receptors or have sedative property. Trials have
shown it to be as effective antidepressant as TCAs and may work in some
resistant cases. A faster onset of action is claimed. Mood changes and hot flushes
in menopausal syndrome, some anxiety and eating disorders are also benefited
by venlafaxine. It does not produce the usual side effects of TCAs;
• tends to raise rather than depress BP and is safer in overdose.
• Prominent side effects are nausea, sweating, anxiety, dizziness, impotence and
withdrawal reactions on discontinuation
• Venlafaxine can cause hypertension .
• Venlafaxine is a rapidly metabolized antidepressant with unpleasant
discontinuation effects .
• 2. Duloxetine
• A newer SNRI similar to venla-faxine. It is neither sedative, nor
anticholinergic, nor antihistaminic, nor α blocker.
• SIDE EFFECTS: including g.i. and sexual problems are milder, but some
agitation, insomnia and rise in BP can occur. /Antidepressant efficacy
is comparable to TCAs. Duloxetine is also indicated in panic attacks,
diabetic neuropathic pain, fibromyalgia and stress urinary
incontinence in women (because it increases urethral tone).
• Duloxetine is a dual mechanism antidepressant used for chronic
pain conditions.
ATYPICAL ANTIDEPRESSANTS
• 1. Trazodone
• It is the first atypical anti-depressant; less efficiently blocks 5-HT uptake and has
prominent α adrenergic and weak 5-HT2 antagonistic actions. The latter may
contribute to its antidepressant effect, which nevertheless is modest. It is
sedative but not anticholinergic, causes bradycardia rather than tachycardia, does
not interfere with intracardiac conduction—less prone to cause arrhythmia and
better suited for the elderly. Nausea is felt, especially in the beginning. Mild
anxiolytic effect has been noted and it has benefited cases of OCD.
• Inappropriate, prolonged and painful penile erection (priapism) occurs in few
recipients resulting in impotence in a fraction of these.
• The α1 adrenergic blocking property has been held responsible for this effect as
well as for postural hypotension. In general, trazodone is infrequently used now
in depression.
2. BUPROPION
This inhibitor of DA and NA uptake has excitant rather than sedative
property.
It is metabolized into an amphetamine like compound which can cause
presynaptic release of DA and NA
It can cause insomnia, agitation, dry mouth and nausea, but not sexual side
effects. Seizures occur in over dose and in predisposed patients due to
lowering of seizure threshold.
The dose of 150 mg BD should not be exceeded. It is contraindicated in
eating disorders and in bipolar illness.
Bupropion is infrequently used to treat depression; may be added to a SSRI.
SUMMARY OF THE GENERAL USES OF
ANTIDEPRESSANTS
• 1. Endogenous (major) depression:
• The aim is to relieve symptoms of depression and restore normal
social behaviour.
• The SSRIs are currently used as first choice for their better tolerability,
safety and may be higher efficacy as well.
• The SNRIs and newer atypical agents also offer some advantages.
• The only antidepressants clearly shown to be effective in juvenile
depression are fluoxetine and sertraline
• The TCAs are mostly used as alternatives in non-responsive cases or in
those not tolerating the second generation antidepressants.
• Moclobemide is a well tolerated option for mild to moderate
depression, especially suited for elderly and cardiac patients.
• After a depressive episode has been controlled, continued treatment
at maintenance doses (about 100 mg imipramine/day or equi-valent)
for months is recommended to prevent relapse.
• Discontinuation of the antidepressant may be attempted after 6–12
months. Long-term therapy may be needed in patients who tend to
relapse.
• ECT may be given in the severely depressed, especially initially while
the effect of antidepressants is developing, because no
antidepressant has been clearly demonstrated to act fast enough to
prevent suicide.
• The TCAs or SSRIs must be combined with lithium/
valproate/lamotrigine for bipolar depression, and not used alone due
to risk of switching over to mania.
• Combination of one of the SSRIs with an atypical antipsychotic (such
as olanzapine, aripiprazole or quetiapine) is also accepted as a
treatment option for bipolar depression.
• 2. Obsessive-compulsive and phobic states:
• The SSRIs, particularly fluoxamine, are the drugs of choice due to
better patient acceptability.
• TCAs, especially clomipramine, are highly effective in OCD and panic
disorders: more than 25% improvement occurs in OCD rating scale
and panic attacks are reduced in >75% patients.
• SSRIs and TCAs also reduce compulsive eating in bulimia, and help
patients with body dysmorphic disorder, compulsive buying and
kleptomania, though these habits may not completely die.
• 3. Anxiety disorders:
• Antidepressants, especially SSRIs, exert a delayed but sustained
beneficial effect in many patients of generalized anxiety disorder; may
be used along with a short course of BZDs to cover exacerbations.
SSRIs have also proven helpful in phobic disorders, sustained
treatment of panic attacks and in post-traumatic stress disorder.
• 4. Neuropathic pain:
• Amitriptyline and other TCAs afford considerable relief in diabetic
and some other types of chronic pain. Amitriptyline reduces intensity
of post-herpetic neuralgia, approximately 50% patients.
• The SSRIs are less effective in these conditions. Duloxetine, a SNRI, is
now a first line drug for diabetic neuropathy, fibro-myalgia, etc. Other
drugs useful in neuropathic pain are pregabalin or gabapentin.
Combination of duloxetine + pregabalin may work if monotherapy is
not satisfactory.
• 5. Attention deficit-hyperactivity disorder (ADHD) in children:
• TCAs with less depressant properties like imipramine, nortriptyline
and amoxapine are now first line drugs in this dis-order, comparable
in efficacy to amphetamine-like drugs, with the advantage of less
fluctuating action and fewer behavioural side effects.
• Atomoxetine is a NA reuptake inhibitor unrelated to both TCAs as well
as amphetamine, which is used specifically in ADHD.
• 6. Premature ejaculation
• Most SSRIs and some TCAs, especially clomipramine have the
common property of delaying and in some cases inhibiting ejaculation
(this itself can cause sexual distress). The primary treatment of
premature ejaculation is counselling and behavioural therapy, but this
can be supplemented by drugs. Dapoxetine is a SSRI which has been
specifically introduced for this purpose. It acts rapidly; 60 mg taken 1
hour before intercourse has helped many subjects.
• Clomipramine 10–25 mg three times a day is a slow acting drug which
needs to be taken regularly for maximum benefit. For on demand use,
25 mg may be taken 6 hours before sex.
• 7. Enuresis:
• In children above 5 years, imipramine 25 mg at bedtime is effective,
but bed wetting may again start when the drug is stopped.
• Eldery subjects with bed wetting have also benefited.
• 8. Migraine:
• Amitriptyline has some prophy-lactic value, especially in patients with
mixed headaches.
• 9. Pruritus: Some tricyclics have antipruritic action. Topical doxepin
has been used to relieve itching in atopic dermatitis, lichen simplex,
etc.
• NOCTADERM 5% cream.
• THANK YOU FOR LISTENING

More Related Content

What's hot

NorEpinephrine ppt.pptx
NorEpinephrine ppt.pptxNorEpinephrine ppt.pptx
NorEpinephrine ppt.pptx
amruthassamsung
 
Chapter 12 Hallucinogens
Chapter 12  HallucinogensChapter 12  Hallucinogens
Chapter 12 Hallucinogens
Justin Gatewood
 
Aspirin toxicity
Aspirin toxicityAspirin toxicity
Aspirin toxicity
khoudorfahda
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
Dr A Abhishake V J
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
DrSana Durvesh-Hassan
 
Drugs in Heart Failure samia
Drugs  in Heart Failure  samiaDrugs  in Heart Failure  samia
Drugs in Heart Failure samia
Nizam Uddin
 
Dopamine, dopaminergic system, parkinson's disease, pharmacotherapy and modul...
Dopamine, dopaminergic system, parkinson's disease, pharmacotherapy and modul...Dopamine, dopaminergic system, parkinson's disease, pharmacotherapy and modul...
Dopamine, dopaminergic system, parkinson's disease, pharmacotherapy and modul...
Dr. Siddhartha Dutta
 
Effective treatment in depression and anxiety
Effective treatment in depression and anxietyEffective treatment in depression and anxiety
Effective treatment in depression and anxiety
Harsh shaH
 
Class antidotes
Class antidotesClass antidotes
Class antidotes
Raghu Prasada
 
PHARMACOTHERAPY OF BRONCHIAL ASTHMA
PHARMACOTHERAPY OF BRONCHIAL ASTHMAPHARMACOTHERAPY OF BRONCHIAL ASTHMA
PHARMACOTHERAPY OF BRONCHIAL ASTHMA
Manoj Kumar
 
Pharmacotherapy of depression
Pharmacotherapy of depressionPharmacotherapy of depression
Pharmacotherapy of depression
Dr.Ameya Puranik
 
Psychopharmacology
Psychopharmacology Psychopharmacology
Psychopharmacology
Lenie Rose Julia
 
Anti-Parkinson Drugs
Anti-Parkinson DrugsAnti-Parkinson Drugs
Anti-Parkinson Drugs
vansh raina
 
Congestive Heart Failure and Drugs used in CCF by Dr. Pawan
Congestive Heart Failure and Drugs used in CCF by Dr. PawanCongestive Heart Failure and Drugs used in CCF by Dr. Pawan
Congestive Heart Failure and Drugs used in CCF by Dr. Pawan
Dr. Pawan Kumar B
 
Dopamine Receptors by Manisha
Dopamine Receptors by ManishaDopamine Receptors by Manisha
Dopamine Receptors by Manisha
Sachin kumar
 
Benzodiazepines
BenzodiazepinesBenzodiazepines
Benzodiazepines
Adonis Sfera, MD
 
Atypical antipsychotics
Atypical antipsychoticsAtypical antipsychotics
Atypical antipsychotics
Karrar Husain
 
ANTIEPILEPTIC_DRUGS .ppt
ANTIEPILEPTIC_DRUGS .pptANTIEPILEPTIC_DRUGS .ppt
ANTIEPILEPTIC_DRUGS .ppt
ClinicalPharmacist1
 
Pharmacology of stimulants, depressants, and hallucinogens
Pharmacology of stimulants, depressants, and hallucinogensPharmacology of stimulants, depressants, and hallucinogens
Pharmacology of stimulants, depressants, and hallucinogens
Dr. DawnElise Snipes ★AllCEUs★ Unlimited Counselor Training
 
Anticonvulsant drugs
Anticonvulsant drugsAnticonvulsant drugs
Anticonvulsant drugs
ZeenathAli2
 

What's hot (20)

NorEpinephrine ppt.pptx
NorEpinephrine ppt.pptxNorEpinephrine ppt.pptx
NorEpinephrine ppt.pptx
 
Chapter 12 Hallucinogens
Chapter 12  HallucinogensChapter 12  Hallucinogens
Chapter 12 Hallucinogens
 
Aspirin toxicity
Aspirin toxicityAspirin toxicity
Aspirin toxicity
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
 
Drugs in Heart Failure samia
Drugs  in Heart Failure  samiaDrugs  in Heart Failure  samia
Drugs in Heart Failure samia
 
Dopamine, dopaminergic system, parkinson's disease, pharmacotherapy and modul...
Dopamine, dopaminergic system, parkinson's disease, pharmacotherapy and modul...Dopamine, dopaminergic system, parkinson's disease, pharmacotherapy and modul...
Dopamine, dopaminergic system, parkinson's disease, pharmacotherapy and modul...
 
Effective treatment in depression and anxiety
Effective treatment in depression and anxietyEffective treatment in depression and anxiety
Effective treatment in depression and anxiety
 
Class antidotes
Class antidotesClass antidotes
Class antidotes
 
PHARMACOTHERAPY OF BRONCHIAL ASTHMA
PHARMACOTHERAPY OF BRONCHIAL ASTHMAPHARMACOTHERAPY OF BRONCHIAL ASTHMA
PHARMACOTHERAPY OF BRONCHIAL ASTHMA
 
Pharmacotherapy of depression
Pharmacotherapy of depressionPharmacotherapy of depression
Pharmacotherapy of depression
 
Psychopharmacology
Psychopharmacology Psychopharmacology
Psychopharmacology
 
Anti-Parkinson Drugs
Anti-Parkinson DrugsAnti-Parkinson Drugs
Anti-Parkinson Drugs
 
Congestive Heart Failure and Drugs used in CCF by Dr. Pawan
Congestive Heart Failure and Drugs used in CCF by Dr. PawanCongestive Heart Failure and Drugs used in CCF by Dr. Pawan
Congestive Heart Failure and Drugs used in CCF by Dr. Pawan
 
Dopamine Receptors by Manisha
Dopamine Receptors by ManishaDopamine Receptors by Manisha
Dopamine Receptors by Manisha
 
Benzodiazepines
BenzodiazepinesBenzodiazepines
Benzodiazepines
 
Atypical antipsychotics
Atypical antipsychoticsAtypical antipsychotics
Atypical antipsychotics
 
ANTIEPILEPTIC_DRUGS .ppt
ANTIEPILEPTIC_DRUGS .pptANTIEPILEPTIC_DRUGS .ppt
ANTIEPILEPTIC_DRUGS .ppt
 
Pharmacology of stimulants, depressants, and hallucinogens
Pharmacology of stimulants, depressants, and hallucinogensPharmacology of stimulants, depressants, and hallucinogens
Pharmacology of stimulants, depressants, and hallucinogens
 
Anticonvulsant drugs
Anticonvulsant drugsAnticonvulsant drugs
Anticonvulsant drugs
 

Similar to Antidepressants BY Dise.pptx

Antidepressants- Pharma.pptx
Antidepressants- Pharma.pptxAntidepressants- Pharma.pptx
Antidepressants- Pharma.pptx
Aymanshahzad4
 
antidepressants-210723100900.pdf
antidepressants-210723100900.pdfantidepressants-210723100900.pdf
antidepressants-210723100900.pdf
ChintuCH1
 
Antidepressants Pharmacology
Antidepressants  PharmacologyAntidepressants  Pharmacology
Antidepressants Pharmacology
Koppala RVS Chaitanya
 
CNS - disorders , symptoms and treatment
CNS - disorders , symptoms and treatment CNS - disorders , symptoms and treatment
CNS - disorders , symptoms and treatment
Areej Abu Hanieh
 
Mahi anti depressants
Mahi anti depressantsMahi anti depressants
Mahi anti depressants
Mahi Yeruva
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
shiva25shankar
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
Subramani Parasuraman
 
Antidepressants.pptx
Antidepressants.pptxAntidepressants.pptx
Antidepressants.pptx
A M O L D E O R E
 
Antidepressants.pptx
Antidepressants.pptxAntidepressants.pptx
Antidepressants.pptx
WrapzeeTech
 
Anti-Depressant
Anti-Depressant Anti-Depressant
Anti-Depressant
ASHISH GAKKHAR
 
Pharmacological management of depression
Pharmacological management of depressionPharmacological management of depression
Pharmacological management of depression
Priyash Jain
 
Depression
DepressionDepression
Depression
Amiya ghosh
 
Antidepressants_Hand Out.pdf
Antidepressants_Hand Out.pdfAntidepressants_Hand Out.pdf
Antidepressants_Hand Out.pdf
muhammadaqibkhattak4
 
Psychopharmacology.pptx
Psychopharmacology.pptxPsychopharmacology.pptx
Psychopharmacology.pptx
DeniseYaso
 
ANTIDEPRESSANTS.pptx
ANTIDEPRESSANTS.pptxANTIDEPRESSANTS.pptx
ANTIDEPRESSANTS.pptx
KisukeUrahara28
 
Antidepressant pharmacology
Antidepressant pharmacology Antidepressant pharmacology
Antidepressant pharmacology
Ahmed Morgan
 
Basic Pharmacology of Antidepressants.ppt
Basic Pharmacology of Antidepressants.pptBasic Pharmacology of Antidepressants.ppt
Basic Pharmacology of Antidepressants.ppt
NorhanKhaled15
 
GROUP NO 6 PPT.pptx
GROUP NO 6 PPT.pptxGROUP NO 6 PPT.pptx
GROUP NO 6 PPT.pptx
ShumailaQadir2
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
Dr. Sriram Raghavendran
 
Clozapine
ClozapineClozapine
Clozapine
Rami James
 

Similar to Antidepressants BY Dise.pptx (20)

Antidepressants- Pharma.pptx
Antidepressants- Pharma.pptxAntidepressants- Pharma.pptx
Antidepressants- Pharma.pptx
 
antidepressants-210723100900.pdf
antidepressants-210723100900.pdfantidepressants-210723100900.pdf
antidepressants-210723100900.pdf
 
Antidepressants Pharmacology
Antidepressants  PharmacologyAntidepressants  Pharmacology
Antidepressants Pharmacology
 
CNS - disorders , symptoms and treatment
CNS - disorders , symptoms and treatment CNS - disorders , symptoms and treatment
CNS - disorders , symptoms and treatment
 
Mahi anti depressants
Mahi anti depressantsMahi anti depressants
Mahi anti depressants
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Antidepressants.pptx
Antidepressants.pptxAntidepressants.pptx
Antidepressants.pptx
 
Antidepressants.pptx
Antidepressants.pptxAntidepressants.pptx
Antidepressants.pptx
 
Anti-Depressant
Anti-Depressant Anti-Depressant
Anti-Depressant
 
Pharmacological management of depression
Pharmacological management of depressionPharmacological management of depression
Pharmacological management of depression
 
Depression
DepressionDepression
Depression
 
Antidepressants_Hand Out.pdf
Antidepressants_Hand Out.pdfAntidepressants_Hand Out.pdf
Antidepressants_Hand Out.pdf
 
Psychopharmacology.pptx
Psychopharmacology.pptxPsychopharmacology.pptx
Psychopharmacology.pptx
 
ANTIDEPRESSANTS.pptx
ANTIDEPRESSANTS.pptxANTIDEPRESSANTS.pptx
ANTIDEPRESSANTS.pptx
 
Antidepressant pharmacology
Antidepressant pharmacology Antidepressant pharmacology
Antidepressant pharmacology
 
Basic Pharmacology of Antidepressants.ppt
Basic Pharmacology of Antidepressants.pptBasic Pharmacology of Antidepressants.ppt
Basic Pharmacology of Antidepressants.ppt
 
GROUP NO 6 PPT.pptx
GROUP NO 6 PPT.pptxGROUP NO 6 PPT.pptx
GROUP NO 6 PPT.pptx
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Clozapine
ClozapineClozapine
Clozapine
 

More from Xavier875943

BONE AND JOINT INFECTIONS.pptx
BONE AND JOINT INFECTIONS.pptxBONE AND JOINT INFECTIONS.pptx
BONE AND JOINT INFECTIONS.pptx
Xavier875943
 
Medical student lecture Obstetric anaesthesia_074208.pptx
Medical student lecture Obstetric anaesthesia_074208.pptxMedical student lecture Obstetric anaesthesia_074208.pptx
Medical student lecture Obstetric anaesthesia_074208.pptx
Xavier875943
 
ACUTE KIDNEY INJURY.pptx
ACUTE KIDNEY INJURY.pptxACUTE KIDNEY INJURY.pptx
ACUTE KIDNEY INJURY.pptx
Xavier875943
 
Urinary tract infection in children.pptx
Urinary tract infection in children.pptxUrinary tract infection in children.pptx
Urinary tract infection in children.pptx
Xavier875943
 
RENAL REPLACEMENT THERAPY.pptx
RENAL REPLACEMENT THERAPY.pptxRENAL REPLACEMENT THERAPY.pptx
RENAL REPLACEMENT THERAPY.pptx
Xavier875943
 
SHORT STATURE.pptx
SHORT STATURE.pptxSHORT STATURE.pptx
SHORT STATURE.pptx
Xavier875943
 
DISORDERS OF PUBERTY.pptx
DISORDERS OF PUBERTY.pptxDISORDERS OF PUBERTY.pptx
DISORDERS OF PUBERTY.pptx
Xavier875943
 
ENURESIS in Paediatrics.pptx
ENURESIS in Paediatrics.pptxENURESIS in Paediatrics.pptx
ENURESIS in Paediatrics.pptx
Xavier875943
 
JAUNDICE Dr Njoku.pptx
JAUNDICE Dr Njoku.pptxJAUNDICE Dr Njoku.pptx
JAUNDICE Dr Njoku.pptx
Xavier875943
 
Burkitt Lymphoma GROUP A BATCH 2 PRESENTATION (1).pptx
Burkitt Lymphoma GROUP A BATCH 2 PRESENTATION  (1).pptxBurkitt Lymphoma GROUP A BATCH 2 PRESENTATION  (1).pptx
Burkitt Lymphoma GROUP A BATCH 2 PRESENTATION (1).pptx
Xavier875943
 
IMMUNIZATION.pptx
IMMUNIZATION.pptxIMMUNIZATION.pptx
IMMUNIZATION.pptx
Xavier875943
 
MSL PAEDIATRIC HIV(2) COPY.pptx
MSL  PAEDIATRIC HIV(2) COPY.pptxMSL  PAEDIATRIC HIV(2) COPY.pptx
MSL PAEDIATRIC HIV(2) COPY.pptx
Xavier875943
 
CONGENITAL RENAL ABNORMALITIES By Dr. Enobong Runcie(0).pptx
CONGENITAL RENAL ABNORMALITIES By Dr. Enobong Runcie(0).pptxCONGENITAL RENAL ABNORMALITIES By Dr. Enobong Runcie(0).pptx
CONGENITAL RENAL ABNORMALITIES By Dr. Enobong Runcie(0).pptx
Xavier875943
 
RENAL and ALIMENTARY CHANGES IN PREGNANCY.pptx
RENAL and ALIMENTARY CHANGES IN PREGNANCY.pptxRENAL and ALIMENTARY CHANGES IN PREGNANCY.pptx
RENAL and ALIMENTARY CHANGES IN PREGNANCY.pptx
Xavier875943
 
chronic_liver_disease.ppt
chronic_liver_disease.pptchronic_liver_disease.ppt
chronic_liver_disease.ppt
Xavier875943
 
GENERAL INTRODUCTION TO CHEMICAL PATHOLOGY-SPECIMENS COLLECTION BY DR ABUDU...
GENERAL INTRODUCTION TO CHEMICAL PATHOLOGY-SPECIMENS   COLLECTION BY DR ABUDU...GENERAL INTRODUCTION TO CHEMICAL PATHOLOGY-SPECIMENS   COLLECTION BY DR ABUDU...
GENERAL INTRODUCTION TO CHEMICAL PATHOLOGY-SPECIMENS COLLECTION BY DR ABUDU...
Xavier875943
 
WATER AND ELECTROLYTE BALANCE.pptx
WATER AND ELECTROLYTE BALANCE.pptxWATER AND ELECTROLYTE BALANCE.pptx
WATER AND ELECTROLYTE BALANCE.pptx
Xavier875943
 
URINALYSIS CHEM PATH.pptx
URINALYSIS CHEM PATH.pptxURINALYSIS CHEM PATH.pptx
URINALYSIS CHEM PATH.pptx
Xavier875943
 
ACUTE DYSTONIC REACTION new.pptx
ACUTE DYSTONIC REACTION new.pptxACUTE DYSTONIC REACTION new.pptx
ACUTE DYSTONIC REACTION new.pptx
Xavier875943
 
Classification of psychiatric disorders by Dr. Fatima.ppt
Classification of psychiatric disorders by Dr. Fatima.pptClassification of psychiatric disorders by Dr. Fatima.ppt
Classification of psychiatric disorders by Dr. Fatima.ppt
Xavier875943
 

More from Xavier875943 (20)

BONE AND JOINT INFECTIONS.pptx
BONE AND JOINT INFECTIONS.pptxBONE AND JOINT INFECTIONS.pptx
BONE AND JOINT INFECTIONS.pptx
 
Medical student lecture Obstetric anaesthesia_074208.pptx
Medical student lecture Obstetric anaesthesia_074208.pptxMedical student lecture Obstetric anaesthesia_074208.pptx
Medical student lecture Obstetric anaesthesia_074208.pptx
 
ACUTE KIDNEY INJURY.pptx
ACUTE KIDNEY INJURY.pptxACUTE KIDNEY INJURY.pptx
ACUTE KIDNEY INJURY.pptx
 
Urinary tract infection in children.pptx
Urinary tract infection in children.pptxUrinary tract infection in children.pptx
Urinary tract infection in children.pptx
 
RENAL REPLACEMENT THERAPY.pptx
RENAL REPLACEMENT THERAPY.pptxRENAL REPLACEMENT THERAPY.pptx
RENAL REPLACEMENT THERAPY.pptx
 
SHORT STATURE.pptx
SHORT STATURE.pptxSHORT STATURE.pptx
SHORT STATURE.pptx
 
DISORDERS OF PUBERTY.pptx
DISORDERS OF PUBERTY.pptxDISORDERS OF PUBERTY.pptx
DISORDERS OF PUBERTY.pptx
 
ENURESIS in Paediatrics.pptx
ENURESIS in Paediatrics.pptxENURESIS in Paediatrics.pptx
ENURESIS in Paediatrics.pptx
 
JAUNDICE Dr Njoku.pptx
JAUNDICE Dr Njoku.pptxJAUNDICE Dr Njoku.pptx
JAUNDICE Dr Njoku.pptx
 
Burkitt Lymphoma GROUP A BATCH 2 PRESENTATION (1).pptx
Burkitt Lymphoma GROUP A BATCH 2 PRESENTATION  (1).pptxBurkitt Lymphoma GROUP A BATCH 2 PRESENTATION  (1).pptx
Burkitt Lymphoma GROUP A BATCH 2 PRESENTATION (1).pptx
 
IMMUNIZATION.pptx
IMMUNIZATION.pptxIMMUNIZATION.pptx
IMMUNIZATION.pptx
 
MSL PAEDIATRIC HIV(2) COPY.pptx
MSL  PAEDIATRIC HIV(2) COPY.pptxMSL  PAEDIATRIC HIV(2) COPY.pptx
MSL PAEDIATRIC HIV(2) COPY.pptx
 
CONGENITAL RENAL ABNORMALITIES By Dr. Enobong Runcie(0).pptx
CONGENITAL RENAL ABNORMALITIES By Dr. Enobong Runcie(0).pptxCONGENITAL RENAL ABNORMALITIES By Dr. Enobong Runcie(0).pptx
CONGENITAL RENAL ABNORMALITIES By Dr. Enobong Runcie(0).pptx
 
RENAL and ALIMENTARY CHANGES IN PREGNANCY.pptx
RENAL and ALIMENTARY CHANGES IN PREGNANCY.pptxRENAL and ALIMENTARY CHANGES IN PREGNANCY.pptx
RENAL and ALIMENTARY CHANGES IN PREGNANCY.pptx
 
chronic_liver_disease.ppt
chronic_liver_disease.pptchronic_liver_disease.ppt
chronic_liver_disease.ppt
 
GENERAL INTRODUCTION TO CHEMICAL PATHOLOGY-SPECIMENS COLLECTION BY DR ABUDU...
GENERAL INTRODUCTION TO CHEMICAL PATHOLOGY-SPECIMENS   COLLECTION BY DR ABUDU...GENERAL INTRODUCTION TO CHEMICAL PATHOLOGY-SPECIMENS   COLLECTION BY DR ABUDU...
GENERAL INTRODUCTION TO CHEMICAL PATHOLOGY-SPECIMENS COLLECTION BY DR ABUDU...
 
WATER AND ELECTROLYTE BALANCE.pptx
WATER AND ELECTROLYTE BALANCE.pptxWATER AND ELECTROLYTE BALANCE.pptx
WATER AND ELECTROLYTE BALANCE.pptx
 
URINALYSIS CHEM PATH.pptx
URINALYSIS CHEM PATH.pptxURINALYSIS CHEM PATH.pptx
URINALYSIS CHEM PATH.pptx
 
ACUTE DYSTONIC REACTION new.pptx
ACUTE DYSTONIC REACTION new.pptxACUTE DYSTONIC REACTION new.pptx
ACUTE DYSTONIC REACTION new.pptx
 
Classification of psychiatric disorders by Dr. Fatima.ppt
Classification of psychiatric disorders by Dr. Fatima.pptClassification of psychiatric disorders by Dr. Fatima.ppt
Classification of psychiatric disorders by Dr. Fatima.ppt
 

Recently uploaded

Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
rightmanforbloodline
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 

Antidepressants BY Dise.pptx

  • 1. ANTIDEPRESSANTS BY UKPONG DISE-UTIBE P. PSCHIATRY POSTING [M3] UNIVERSITY OF UYO TEACHING HOSPITAL JANUARY 2023
  • 2. OUTLINE • INTRODUCTION • BRIEF HISTORY OF ANTIDEPRESSANT USE • THERAPEUTICS OF ANTIDEPRESSANT USE • GOOD AND BAD NEWS OF ANTIDEPRESSANT TREATMENT • USE OF ANTIDEPRESSANTS ACROSS LIFE CYCLES • BIOLOGICAL BASIS OF DEPRESSION • CLASSIFICATION OF ANTIDEPRESSANTS • MECHANISM OF ACTION, USES AND SIDE EFFECTS OF EACH ANTIDEPRESSANT • SUMMARY OF THE GENERAL USES OF ANTIDEPRESSANTS
  • 3. INTRODUCTION • These are varied groups of therapeutic agent that significantly elevate the mood of depressed patients. Despite the duration of the discovery of these agents, the precise pharmacological activity of some of them remain unexplained. • The first group of antidepressants to be used were the tricyclic antidepressants which were closely followed by the monoamine oxidase inhibitors. • Recently, a series of highly successful innovative agents have been introduced. These include, selective serotonin reuptake inhibitors (SSRI), Selective Noradrenalin reuptake inhibitors (SNRIS), dual SSRI and SNRI, dual 5HT2 antagonist/5HT reuptake inhibitors, NE/DA reuptake inhibitors.
  • 4. BRIEF HISTORY OF ANTIDEPRESSANT USE • The history of antidepressants began, by chance, in the 1950s. Chemists developing a new treatment for tuberculosis tested the drug iproniazid on patients at Seaview Hospital on Staten Island. It was a crucial step in the history of depression treatment, as these patients experienced a dramatic change in well-being. Formerly lethargic and sad, they now reported better mood, increased appetite, and improved sleep.
  • 5. THERAPEUTICS OF ANTIDEPRESSANT USE The Five R’s of Antidepressant Treatment 3 R’s use to describe improvement Response (At least 50% Reduction in symptom) Remission (All symptoms disappear for 6-12 months) Recovery (Symptoms disappear for over 12 months)
  • 6. • 2 R’s used to describe worsening • Relapse • (Worsening before remission) • Reoccurrence • (Worsening after recovery)
  • 7. Good news/Bad news about Antidepressant treatment • Good news • All antidepressants show about the same response (getting better) after 8 weeks (50 - 75% of patients) • Bad news • Raising the bar of “getting better” dims the success rate; 50% may show remission in 6 months; 75% in 12 months. • All antidepressants significantly reduce relapse rates during the first 6-12 months after initial response to the medication.
  • 8. Use of antidepressants across life cycle • Children: currently no antidepressant has been expressly approved for treatment of depression in children (used in OCD) • Adolescents: Better than children as in adults. Synaptic restructuring generally occurs after the age of 6 years.
  • 9. Biological Basis of Depression • 1. Monoamine Hypothesis: 1st major theory about biological etiology of depression. It predicts that the underlying pathophysiologic basis of depression is a depletion in the levels of serotonin, norepinephrine, and/or dopamine in the central nervous system.
  • 10. • 2. Neurotransmitter Receptor Hypothesis. Problem with receptors for the key monoamine neurotransmitters
  • 11. • 3. Monoamine Hypothesis of Gene Expression. BASED ON: • Lack of clear and convincing evidence of absolute monoamine deficiency • No clear and convincing evidence of that excess or deficiencies of mono amines account for depression • Clear evidence that systems do not respond normally.
  • 12. • POSSIBILITIES: • Pseudo monoamine deficiency due to a deficiency in signal transduction from neurotransmitter to receptor (molecular functioning) • Abnormal molecular activity; post receptor (2nd messenger) problems with intracellular transcription factors that control gene regulation. • Abnormality in signal transduction from monoamine receptors. • Brain Derived Neurotrophic Factor (BDNF) may be responsible for repeated depressive episodes and poor response to treatment (supported by decrease in size of hippocampal neurons and impaired function in depression).
  • 13. • 4. Neurokinin Hypothesis of Emotional Dysfunction • Presence of neurokinins in amygdala • Presence of neurokinins in areas where mono amines are in abundance. •
  • 14. CLASSIFICATION OF ANTIDEPRESSANTS 1. MONOAMINEOXIDASE INHIBITORS A. REVERSIBLE INHIBITORS OF MAO-A (RIMAS) • Moclobemide, • Clorgyline B. IRREVERSIBLE INHIBITIORS OF MAO-A • Selegiline (Emsam), • phenelzine (Nardil), • tranylcypromine (Parnate), • isocarboxazid (Marplan).
  • 15. 2. Tricyclic antidepressants (TCAs) A. NA + 5-HT reuptake inhibitors • Imipramine, • Amitriptyline • Trimipramine, • Doxepin, • Dothiepin, • Clomipramine
  • 16. B. Predominantly NA reuptake inhibitors • Desipramine, • Nortriptyline, • Amoxapine, • Reboxetine
  • 17. 3. Selective serotonin reuptake inhibitors (SSRIs) • Fluoxetine, • Fluvoxamine, • Paroxetine, • Sertraline, • Citalopram, • Escitalopram, • Dapoxetine
  • 18. 4. Serotonin and noradrenaline reuptake inhibitors (SNRIs) • Venlafaxine, • Duloxetine 5. Atypical antidepressants Trazodone, • Mianserin, • Mirtazapine, • Bupropion, • Tianeptine, • Amineptine, • Atomoxetine
  • 19. IRREVERSIBLE INHIBITIORS OF MAO-A MECHANISM OF ACTION • Uniquely among antidepressants, MAOI’s increase synaptic levels of all three catecholamines (serotonin, norepinephrine, and dopamine). • Because of this, MAOI’s are among the most effective of all antidepressants, especially in the subtype of depression known as atypical depression . • Atypical depression is characterized by mood reactivity, interpersonal rejection sensitivity, increased appetite, hypersomnia, and leaden paralysis (the sensation that one’s arms are too heavy to lift).
  • 20. • Selegiline is unique, however, in that it is sele ctive for the B-subtype of MAO, whereas the other three are non-selective and hit both MAO-A and MAO-B.
  • 21. SIDE EFFECTS • anticholinergic and • antihistaminic effects discussed with the tricyclics, • multiple drug-drug interactions, • withdrawal symptoms, and potentially • fatal hypertensive events. • Because of these considerations, MAOI’s are not prescribed very often in modern psychiatry and are typically used as a “last resort” after a patient has failed multiple other medications from several different classes first.
  • 22. INTERACTIONS • (i) Cheese reaction Certain varieties of cheese, beer, wines, pickled meat and fish, yeast extract contain large quantities of tyramine, dopa, etc. In MAO inhibited patients these indirectly acting sympathomimetic amines escape degradation in the intestinal wall and liver → reaching into systemic circulation they displace and release large amounts of NA from transmitter loaded adrenergic nerve endings → hypertensive crisis, cerebrovascular accidents. When such a reaction occurs, it can be treated by i.v. injection of a rapidly acting α blocker, e.g. phentolamine. Prazosin or chlorpromazine are alternatives.
  • 23. • (ii) Cold and cough remedies They contain ephedrine or other sympathomimetics—hypertensive reaction can occur. • (iii) Reserpine, guanethidine, tricyclic antidepressants Excitement, rise in BP and body temperature can occur when these drugs are given to a patient on MAO inhibitors. This is due to their initial NA releasing or uptake blocking action. • (iv) Levodopa Excitement and hypertension occur due to increase in biological t½ of DA and NA that are produced from levodopa. • (v) Antiparkinsonian anticholinergics Hallucinations and symptoms similar to those of atropine poisoning occur. • (vi) Barbiturates, alcohol, opioids, antihistamines Action of these drugs is intensified and prolonged. Respiration may fail. • (vii) Pethidine High fever, sweating, excitation, delirium, convulsions and severe respiratory depression have occurred. The most accepted explanation is— MAO inhibitors retard hydrolysis of pethidine but not its demethylation. Thus, excess of norpethidine (normally a minor metabolite—see p. 475) is produced which has excitatory actions.
  • 24. REVERSIBLE INHIBITORS OF MAO-A (MOCLOBEMIDE) • MECHANISM OF ACTION • It is a reversible and selective MAO-A inhibitor with short duration of action; full MAO activity is restored within 1–2 days of stopping the drug. Because of competitive enzyme inhibition, tyramine is able to displace it from the enzyme, so that potentiation of pressor response to ingested amines is minor, and dietary restrictions are not required. Clinical trials have shown moclobemide to be an efficacious antidepressant, comparable to TCAs, except in severe cases. and is safer in overdose. • This makes it a particularly good option in elderly patients and in those with heart disease. • Dose: 150 mg BD–TDS (max 600 mg/day) • RIMAREX, TRIMA 150, 300 mg tabs.
  • 25. SIDE EFFECTS • Nausea, • dizziness, • headache, • insomnia, • rarely excitement and • liver damage.
  • 26. INTERACTIONS • Chances of interaction with other drugs and alcohol are remote, but caution is advised while coprescribing pethidine, SSRIs and TCAs. • NOTE: It has emerged as well tolerated alternative to mild and moderate depression and for social phobia
  • 27.
  • 28. TRICYCLIC ANTIDEPRESSANTS • Now we come to the oldest class of antidepressants, and some of the first drugs to be officially prescribed for that purpose: the tricyclic antidepressants (often shortened to just “tricyclics” or “TCA’s”). You can generally recognize TCA’s by their name, as they usually have the suffixes–triptyline (as in amitriptyline and nortriptyline) or –ipramine (as in clomipramine and imipramine).
  • 29. MECHANISM OF ACTION OF TCA • First, TCA’s inhibit the reuptake of both serotonin and norepinephrine (similar to SNRI’s). This is the action that is primarily responsible for their antidepressant effects. • Second, TCA’s antagonize acetylcholine and histamine , which accounts more for their side effect profile than their antidepressant efficacy. • Third, TCA’s are known to work as sodium and calcium channel inhibitors as well. Clinically, this property may account for some of their analgesic properties (like duloxetine, they are helpful for some chronic pain conditions).
  • 30. SIDE EFFECTS OF TCA • Anticholinergic side effects, including dry mouth, itchy eyes, blurry vision, constipation, urinary retention, memory impairment, and increased body temperature. • Antagonism of histamine results in a diphenhydramine-like effect, with drowsiness and sedation being common complaints while on a tricyclic.
  • 31. • TOXICITY OF TCA OVERDOSE • They have a therapeutic index of 7, (meaning that taking just 7 times the normal amount of the drug could cause death). Slowing these ion channels affects both cardiac and neuronal conduction, leading to arrhythmias and altered mental status or coma. NOTE: A wide QRS in the context of suspected overdose is likely TCA overdose . Treatment is sodium bicarbonate .
  • 32. • In summary • TCA’s act as agonists at two neurotransmitters, antagonists at another two, and inhibitors of two ion channels. PNEUMONIC TCA’s increase serotonin and norepinephrine , block acetylcholine and histamine , and inhibit sodium and calcium ion channels. TCA’s affect T rans, C hans, and A ns.
  • 33. INTERACTIONS • 1. TCAs potentiate directly acting sympathomi-metic amines (present in cold/asthma remedies). Adrenaline containing local anaesthetic should be avoided. However, TCAs attenuate the action of indirect sympathomi-metics (ephedrine, tyramine). • 2. TCAs abolish the antihypertensive action of guanethidine and clonidine by preventing their transport into adrenergic neurones. • 3. TCAs potentiate CNS depressants, including alcohol and antihistaminics. • 4. Phenytoin, phenylbutazone, aspirin and Chlopromazine(antipsychotic) can displace TCAs from protein binding sites and cause transient overdose symptoms.
  • 34. • 5. Phenobarbitone competitively inhibits as well as induces imipramine metabolism. • Carbamazepine and other enzyme inducers enhance metabolism of TCAs. • 6. SSRIs inhibit metabolism of several drugs (see later) including TCAs— dangerous toxi-city can occur if the two are given concur-rently. • 7. By their anticholinergic property, TCAs delay gastric emptying and retard their own as well as other drug’s absorption. However, digoxin and tetracyclines may be more completely absorbed. When used together, the anticho-linergic action of neuroleptics and TCAs may add up. • 8. MAO inhibitors—dangerous hypertensive crisis with excitement and hallucinations has occurred when given with TCAs.
  • 35. IMIPRAMINE The first antidepressant ever developed! Imipramine is a prototypical TCA, so everything we’ve talked about thus far applies. One thing that sets imipramine apart is that it is sometimes used for management of nocturnal enuresis, or bed wetting, in children. The anticholinergic effect of imipramine prevents the bladder from contracting, thus holding the urine. Because of its side effects, it is not used as a first-line agent but can be useful in refractory cases
  • 36. CLOMIPRAMINE • Clomipramine (Anafranil) is another TCA that can be used to treat depression. However, clomipramine is unique in that it is considered to be the gold-standard for medication treatment of obsessive- compulsive disorder (OCD) , as it was found in several randomized controlled trials to be more effective than SSRI’s. Due to its higher side effect burden, however, clomipramine should be reserved for more severe or refractory cases of OCD, with SSRI’s as the first-line option.
  • 37. AMITRIPTYLINE AND NORTRIPTYLINE • Two other commonly prescribed TCA’s are amitriptyline (Elavil) and nortriptyline (Pamelor). Both are prototypical TCA’s, but in addition to depression, you will also see them prescribed for chronic pain issues, such as diabetic peripheral neuropathy, chronic low back pain, or pelvic pain. • Compared to amitriptyline, nortriptyline tends to be much less associated with sedation, orthostatic hypotension, and falls (owing to less antihistaminergic and anticholinergic effects). For this reason, it is preferred for elderly patients for whom sedation and falls can be very big deals.
  • 38. • Amoxapine • This tetracyclic compound is unusual in that it blocks dopamine D2 receptors in addition to inhibiting NA reuptake. It is chemically related to the antipsychotic drug loxapine and has mixed antidepressant + neuroleptic properties—offers advantage for patients with psychotic depression. Risk of extrapyramidal side effects is also there. Seizures (including status epilepticus) occur in its overdose.
  • 39. • Reboxetine • This is a newer selective NA reuptake blocker with weak effect on 5- HT reuptake. Antimuscarinic and sedative actions are minimal. It appears to produce fewer side effects and may be safer in overdose than the older TCAs. • Side effects are insomnia, palpitation, dry mouth, constipation, sexual distress and urinary symptoms. Dose: NAREBOX 4, 8 mg tab. 4 mg BD or 8 mg OD
  • 40.
  • 41.
  • 42. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) • These drugs work by inhibiting the reuptake of serotonin, effectively increasing the amount of serotonin active and available in the synaptic cleft • One thing to counsel patients on before starting an SSRI is how long they can take to work. In multiple studies, it has been shown that full treatment efficacy is often not reached until 4 to 6 weeks (although typically some benefit is noticed within the first 2 weeks). Patients can sometimes feel like stopping the drug early, as the side effects (like diarrhea) are immediate, while the desired effects can take several weeks.
  • 43. Antidepressant Profile of SSRI • Starting dose usually the same as the maintenance dose. • Response is frequently complete with remission of symptoms. • Target symptoms do not worsen when treatment initiated.
  • 44. SIDE EFFECTS • Commonly cause; • nausea and GI upset, • headache, • restlessness, and insomnia; • may be less effective for severe depressive episodes;
  • 45. • Contraindications: manic episode, concomitant use of MAOIs • Interactions: alcohol, anticoagulants, anticonvulsants, antipsychotics, BDZs, B-blockers
  • 46.
  • 47. Fluoxetine • A bicyclic compound, is the first SSRI to be introduced, and the longest acting. • Its plasma t½ is 2 days and that of its active demethylated metabolite is 7– 10 days. It has been approved for use in children 7 years or older for depression and OCD on the basis of similar efficacy and side effect profile as in adults, but should be given to children only when psychotherapy fails. • Agitation and dermatological reactions are more frequent than other SSRIs Because of slower onset of antidepressant effect, it is considered less suitable for patients needing rapid effect, but is more appropriate for poorly compliant patients. Its stimulant effect could worsen patients showing agitation. • Fluoxetine has a very long half-life, lasting 1 to 2 weeks
  • 48. Sertraline • This SSRI has gained popularity, because in clinical trials fewer patients stopped sertraline due to side effects. • Efficacy in juvenile depression has been demonstrated, and it is recommended for anxiety and post-traumatic stress disorder (PTSD) as well. • Drug interactions due to inhibition of CYP isoenzymes are less likely to occur with this SSRI. Its plasma t½ is 26 hours and it produces a still longer-lasting active metabolite. • NOTE: Sertraline has more GI side effects but is safe when pregnant or breastfeeding .
  • 49. Citalopram • This SSRI shares with sertraline a lower propensity to cause drug interactions.Its t½ is 33 hours and no active metabolite is known. However, few deaths due to overdose of citalopram are on record, because of which it is to be avoided in patients likely to attempt suicide. Citalopram is the preferred SSRI for mood disorders in premenstrual syndrome.
  • 50. Escitalopram • It is the active S(+) enantiomer of citalopram, effective at half the dose, with similar properties. Side effects are milder and safety is improved.
  • 51. Dapoxetine • A SSRI which has been developed and is being promoted for delaying premature ejaculation, a property common to many SSRIs and some TCAs. • Dapoxetine acts rapidly and can be taken 1 hour before sexual intercourse. • Combined with behavioural therapies, it has been found to help many sufferers. • Side effects are nausea, vomiting, loose motions, headache, dizziness and occasionally insomnia. • Dose: 60 mg taken 1 hour before intercourse; older patients 30 mg.
  • 52. • Mode of action: 5-HT and NE reuptake inhibition. • • Common adverse effects: nausea, GI upset, constipation, loss of appetite, dry mouth, dizziness, agitation, insomnia, sexual dysfunction, headache, nervousness, sweating, weakness SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS (SNRIs)
  • 53. • 1. Venlafaxine • A novel antidepressant referred to as SNRI, because it inhibits uptake of both NA and 5-HT but, in contrast to older TCAs, it does not interact with cholinergic, adrenergic or histaminergic receptors or have sedative property. Trials have shown it to be as effective antidepressant as TCAs and may work in some resistant cases. A faster onset of action is claimed. Mood changes and hot flushes in menopausal syndrome, some anxiety and eating disorders are also benefited by venlafaxine. It does not produce the usual side effects of TCAs; • tends to raise rather than depress BP and is safer in overdose. • Prominent side effects are nausea, sweating, anxiety, dizziness, impotence and withdrawal reactions on discontinuation • Venlafaxine can cause hypertension . • Venlafaxine is a rapidly metabolized antidepressant with unpleasant discontinuation effects .
  • 54. • 2. Duloxetine • A newer SNRI similar to venla-faxine. It is neither sedative, nor anticholinergic, nor antihistaminic, nor α blocker. • SIDE EFFECTS: including g.i. and sexual problems are milder, but some agitation, insomnia and rise in BP can occur. /Antidepressant efficacy is comparable to TCAs. Duloxetine is also indicated in panic attacks, diabetic neuropathic pain, fibromyalgia and stress urinary incontinence in women (because it increases urethral tone). • Duloxetine is a dual mechanism antidepressant used for chronic pain conditions.
  • 55. ATYPICAL ANTIDEPRESSANTS • 1. Trazodone • It is the first atypical anti-depressant; less efficiently blocks 5-HT uptake and has prominent α adrenergic and weak 5-HT2 antagonistic actions. The latter may contribute to its antidepressant effect, which nevertheless is modest. It is sedative but not anticholinergic, causes bradycardia rather than tachycardia, does not interfere with intracardiac conduction—less prone to cause arrhythmia and better suited for the elderly. Nausea is felt, especially in the beginning. Mild anxiolytic effect has been noted and it has benefited cases of OCD. • Inappropriate, prolonged and painful penile erection (priapism) occurs in few recipients resulting in impotence in a fraction of these. • The α1 adrenergic blocking property has been held responsible for this effect as well as for postural hypotension. In general, trazodone is infrequently used now in depression.
  • 56. 2. BUPROPION This inhibitor of DA and NA uptake has excitant rather than sedative property. It is metabolized into an amphetamine like compound which can cause presynaptic release of DA and NA It can cause insomnia, agitation, dry mouth and nausea, but not sexual side effects. Seizures occur in over dose and in predisposed patients due to lowering of seizure threshold. The dose of 150 mg BD should not be exceeded. It is contraindicated in eating disorders and in bipolar illness. Bupropion is infrequently used to treat depression; may be added to a SSRI.
  • 57. SUMMARY OF THE GENERAL USES OF ANTIDEPRESSANTS • 1. Endogenous (major) depression: • The aim is to relieve symptoms of depression and restore normal social behaviour. • The SSRIs are currently used as first choice for their better tolerability, safety and may be higher efficacy as well. • The SNRIs and newer atypical agents also offer some advantages. • The only antidepressants clearly shown to be effective in juvenile depression are fluoxetine and sertraline
  • 58. • The TCAs are mostly used as alternatives in non-responsive cases or in those not tolerating the second generation antidepressants. • Moclobemide is a well tolerated option for mild to moderate depression, especially suited for elderly and cardiac patients. • After a depressive episode has been controlled, continued treatment at maintenance doses (about 100 mg imipramine/day or equi-valent) for months is recommended to prevent relapse. • Discontinuation of the antidepressant may be attempted after 6–12 months. Long-term therapy may be needed in patients who tend to relapse.
  • 59. • ECT may be given in the severely depressed, especially initially while the effect of antidepressants is developing, because no antidepressant has been clearly demonstrated to act fast enough to prevent suicide. • The TCAs or SSRIs must be combined with lithium/ valproate/lamotrigine for bipolar depression, and not used alone due to risk of switching over to mania. • Combination of one of the SSRIs with an atypical antipsychotic (such as olanzapine, aripiprazole or quetiapine) is also accepted as a treatment option for bipolar depression.
  • 60. • 2. Obsessive-compulsive and phobic states: • The SSRIs, particularly fluoxamine, are the drugs of choice due to better patient acceptability. • TCAs, especially clomipramine, are highly effective in OCD and panic disorders: more than 25% improvement occurs in OCD rating scale and panic attacks are reduced in >75% patients. • SSRIs and TCAs also reduce compulsive eating in bulimia, and help patients with body dysmorphic disorder, compulsive buying and kleptomania, though these habits may not completely die.
  • 61. • 3. Anxiety disorders: • Antidepressants, especially SSRIs, exert a delayed but sustained beneficial effect in many patients of generalized anxiety disorder; may be used along with a short course of BZDs to cover exacerbations. SSRIs have also proven helpful in phobic disorders, sustained treatment of panic attacks and in post-traumatic stress disorder.
  • 62. • 4. Neuropathic pain: • Amitriptyline and other TCAs afford considerable relief in diabetic and some other types of chronic pain. Amitriptyline reduces intensity of post-herpetic neuralgia, approximately 50% patients. • The SSRIs are less effective in these conditions. Duloxetine, a SNRI, is now a first line drug for diabetic neuropathy, fibro-myalgia, etc. Other drugs useful in neuropathic pain are pregabalin or gabapentin. Combination of duloxetine + pregabalin may work if monotherapy is not satisfactory.
  • 63. • 5. Attention deficit-hyperactivity disorder (ADHD) in children: • TCAs with less depressant properties like imipramine, nortriptyline and amoxapine are now first line drugs in this dis-order, comparable in efficacy to amphetamine-like drugs, with the advantage of less fluctuating action and fewer behavioural side effects. • Atomoxetine is a NA reuptake inhibitor unrelated to both TCAs as well as amphetamine, which is used specifically in ADHD.
  • 64. • 6. Premature ejaculation • Most SSRIs and some TCAs, especially clomipramine have the common property of delaying and in some cases inhibiting ejaculation (this itself can cause sexual distress). The primary treatment of premature ejaculation is counselling and behavioural therapy, but this can be supplemented by drugs. Dapoxetine is a SSRI which has been specifically introduced for this purpose. It acts rapidly; 60 mg taken 1 hour before intercourse has helped many subjects.
  • 65. • Clomipramine 10–25 mg three times a day is a slow acting drug which needs to be taken regularly for maximum benefit. For on demand use, 25 mg may be taken 6 hours before sex.
  • 66. • 7. Enuresis: • In children above 5 years, imipramine 25 mg at bedtime is effective, but bed wetting may again start when the drug is stopped. • Eldery subjects with bed wetting have also benefited.
  • 67. • 8. Migraine: • Amitriptyline has some prophy-lactic value, especially in patients with mixed headaches. • 9. Pruritus: Some tricyclics have antipruritic action. Topical doxepin has been used to relieve itching in atopic dermatitis, lichen simplex, etc. • NOCTADERM 5% cream.
  • 68. • THANK YOU FOR LISTENING